https://www.selleckchem.com/products/ertugliflozin.html Prostate cancer (PC) is the most common form of cancer in males and accounts for many cancer-related deaths. Human cell division cycle associated 5 (CDCA5) may be a useful marker for predicting tumor metastasis and therapeutic target for the treatment of PC patients. In this study, we investigated the role of CDCA5 in prostate cancer progression. Immunohistochemistry was performed on 20 prostate cancer tissue samples. We performed immunohistochemistry on 20 prostate cancer tissue samples. CDCA5, a gene that is differentially expressed in prostate cancer, was screened with The Cancer Genome Atlas database. In both DU145 and PC-3 cells, CDCA5 levels consistently affected cell proliferation, colony formation, apoptosis, migration, and invasion. CDCA5 knockdown significantly inhibited PC cell proliferation, migration, and invasion. Furthermore, the apoptosis of DU145 and PC-3 cells was significantly increased after CDCA5 downregulation. Further investigations revealed that CDCA5 may participate in the development of PC through interaction with TWIST1, CDH1, and CDH2. The present results provide a novel insight into the important and multifaceted role of CDCA5 in PC, indicating that CDCA5 is a promising biomarker and therapeutic target for PC. The present results provide a novel insight into the important and multifaceted role of CDCA5 in PC, indicating that CDCA5 is a promising biomarker and therapeutic target for PC.The biologist Conrad Waddington first coined the term epigenetics, defining it as "the branch of biology that studies the causal interactions between genes and their products and creates a phenotype." The molecular mechanisms underlying epigenetics are complex. Epigenetic changes are rapid, functional, nonstructural, and reversible, and these DNA changes are partly transmissible from one generation to the next. These modifications affect the activation of certain genes but not their basic structure. In